Professional Documents
Culture Documents
Venous Thromboembolism
National Performance Measures And Recent
Guidelines
2
Venous thromboembolism (VTE) = Deep vein
thrombosis (DVT) and Pulmonary embolism (PE)
“The best estimates indicate
that 350,000 to 600,000
Americans each year suffer
from DVT and PE, and that at
least 100,000 deaths may be
directly or indirectly related to
these diseases. This is far too
many, since many of these
deaths can be avoided.
Because the disease
disproportionately affects
older Americans, we can
expect more suffering and
more deaths in the future as
our population ages–unless
we do something about it.”
Annual Incidence of VTE in Olmsted County,
MN: 1966-1995
By Age and Gender
1,200
Annual incidence/100,000
Men
1,000
800
600
Women
Women
400
200
Age
Age group
group (yr)
(yr) 5
Prevention of Venous Thromboembolism
Introduction
• Post-thrombotic syndrome
– Calf swelling and skin pigmentation; venous
ulceration in severe cases
• Up to 43% of patients within 2 years – most mild
Goldhaber SZ, Bounameaux H. Lancet. 2012 May 12; 379:1835-46.
Prevention of Venous Thromboembolism
• The majority (93%) of estimated VTE-related
deaths in the US were due to sudden, fatal PE
(34%) or followed undiagnosed VTE (59%)
Heit JA, Cohen AT, Anderson FA on behalf of the VTE Impact Assessment Group.
9
[Abstract] American Society of Hematology Annual Meeting, 2005.
National Body Position Statements
• Leapfrog1:
PE is “the most common preventable cause of hospital death in
the United States”
• Agency for Healthcare Research and Quality (AHRQ)2:
Thromboprophylaxis is the number 1 patient safety practice
• American Public Health Association (APHA)3:
“The disconnect between evidence and execution as it relates
to DVT prevention amounts to a public health crisis.”
The Leapfrog Group Hospital Quality and Safety Survey. Available at: www.leapfrog.medstat.com/pdf/Final/doc
Shojania KG, et al. Making Healthcare Safer: A Critical Analysis of Patient Safety Practices. AHRQ, 2001. Available
at: www.ahrq.gov/clinic/ptsafety/
White Paper. Deep-vein thrombosis: Advancing awareness to protect patient lives. 2003. Available at:
www.alpha.org/ppp/DVT_White_Paper.pdf 10
Annual cost to treat VTE
• $11,000 per DVT episode per patient
• $17,000 per PE episode per patient
• Recurrence increases hospitalization costs by
20%
• Complications of anticoagulation
• Time lost from work
– Quality of life: venous stasis and pulmonary HTN
11
Consequences of Surgical Complications
14
Acquired Risk Factors
Risk Factor Attributable Risk
Hospitalization/Nursing home 61.2
Trauma 12.5
CHF 11.8
CV catheter 10.5
Varicose veins/stripping 6
Many others….
15
Risk Factors for DVT or PE
Nested Case-Control Study (n=625 case-control pairs)
Surgery
Trauma
Inpatient
Malignancy with chemotherapy
Malignancy without chemotherapy
Central venous catheter or pacemaker
Neurologic disease
Superficial vein thrombosis
Varicose veins/age 45 yr
Varicose veins/age 60 yr
Varicose veins/age 70 yr
CHF, VTE incidental on autopsy
CHF, antemortem VTE/causal for death
Liver disease
0 5 10 15 20 25 50
Odds ratio
16
Independent Risk Factors for VTE after
Major Surgery*:
Olmsted County 1988-97 (n=163)
Risk Factor OR 95% CI P-value
Age (per 10 years) 1.26 1.07, 1.50 0.007
BMI (kg/m2, per 2-fold increase) 2.95 1.49, 5.82 0.002
ICU Length of Stay > 6 Days 3.97 1.46, 10.80 0.007
Central Venous Catheter 2.46 1.21, 5.03 0.013
Immobility Requiring Physical
2.18 1.17, 4.06 0.014
Therapy
Varicose Veins 1.87 1.08, 3.23 0.025
Any Infection 1.68 1.01, 2.82 0.046
Anticoagulation Prophylaxis 0.27 0.12, 0.59 0.001
1000
Cases per 10,000 person-years
100
Recently
hospitalized
10
1
Hospitalized patients Community residents
Heit JA. Mayo Clin Proc. 2001;76:1102 18
Cumulative Incidence of VTE After Primary Hip
or Knee Replacement
3.5
Primary hip
3.0
Primary knee
2.5
VTE
2.0
events
(%) 1.5
1.0
0.5
0.0
0 7 14 21 28 35 42 49 56 63 70 77 84 91
Days
• IMPROVE Registry
– 15,156 medical patients admitted to the hospital
• 184 patients had VTE events
– 45% developed VTE after discharge
70
240
200
160
Cases
120
30/86 (35%) 33/83 (40%)
80
40
0
Moderate High Very High
Use of any form of prophylaxis based on level of risk for venous thromboembolism among 419 Medicare patients from
20 hospitals undergoing major abdominothoracic surgery. Measures were implemented for patients at moderate risk
(35%; 95% CI, 25-46%), at high risk (40%; 95% CI, 29-51%), and at very high risk (39%; 95% CI, 33-45%). Overall
utilization rate for prophylaxis was 38% (95% CI, 33-43%).
Bratzler DW, et al. Arch Intern Med. 1998;158:1909-1912.
Thromboprophylaxis Use in Practice
1992-2002
Prophylaxis
Patient Group Studies Patients Use (any)
Orthopedic surgery 4 20,216 90 % (57-98)
General surgery 7 2,473 73 % (38-98)
Critical care 14 3,654 69 % (33-100)
Gynecology 1 456 66 %
Medical patients 5 1,010 23 % (14-62)
How many patients with COPD, CVA, heart failure, pneumonia, etc
do you have in your hospital that are not on DVT prophylaxis?
24
Prevention of VTE in Medical Patients
• Compression
ultrasound
• CT angiography
30
Pharmacologic Prophylaxis
• Low-dose unfractionated heparin (LDUH)
• Low-molecular weight heparin (LMWH)*
• Fondaparinux*
• Direct inhibitors of activated factor X
– rivaroxaban
• Direct thrombin inhibitors
– dabigatran
• Warfarin
• Aspirin
*Cleared by the kidneys. 31
Approach to Treatment
How long do you treat?
Evidence
Duration of Treatment Grade
First VTE event secondary to a 3 months 1A
reversible factor (“provoked”)
First idiopathic (“unprovoked) VTE At least 3 months 1A
At the end of initial 3-month period Assess for long-term Rx 1C
In the absence of contraindication Long-term Rx 1A
During long-term treatment Assess risk/benefit balance 1C
Recurrent VTE or strong thrombophilia Long-term Rx 1A
VTE secondary to cancer Long-term Rx, preferentially 1A
with LMWH during the first 3- 1C
6 months, then anticoagulate
as long as the cancer is
considered “active”
Multicenter, double-blind
study, patients with first-
ever unprovoked venous
thromboembolism who
had completed 6 to 18
months of oral
anticoagulant treatment
were randomly assigned
to aspirin, 100 mg daily,
or placebo for 2 years
35
Why the need for performance measures?
• Despite widespread publication and
dissemination of guidelines, practices have not
changed at an acceptable pace
– There are still far too many needless deaths from
VTE in the US
36
37
Venous Thromboembolism
Statement of Organization Policy
38
Venous Thromboembolism
Characteristics of Preferred Practices
General
• Protocol selection by multidisciplinary teams
• System for ongoing QI
• Provision for RA/stratification, prophylaxis,
diagnosis, treatment
• QI activity for all phases of care
• Provider education
39
Venous Thromboembolism
Characteristics of Preferred Practices
(cont.)
Risk Assessment/Stratification
• RA on all patients using evidence-based policy
• Documentation in patient record that done
Prophylaxis
• Based on assessment & risk/benefit, efficacy/safety
• Based on formal RA, consistent with accepted,
evidence-based guidelines
40
Venous Thromboembolism
Characteristics of Preferred Practices
(cont.)
Diagnosis
• Objective testing to justify continued initial therapy
Treatment and Monitoring
• Ensure safe anticoagulation, consider setting
• Incorporate Safe Practice 29
• Patient education; consider setting and reading levels
• Guideline-directed therapy
• Address care setting transitions in therapy
41
Surgical Care Improvement Project
First Two VTE Measures Endorsed by NQF
42
Venous Thromboembolism
Technical Advisory Panel (TAP) charge
43
6 Refined Measures That Were Endorsed
44
6 Refined Measures That Were Endorsed
45
6 Refined Measures Endorsed (cont.)
Outcome
Incidence of potentially-preventable VTE – proportion of
patients with hospital-acquired VTE who had NOT received VTE
prophylaxis prior to the event
46
New Guidelines and Controversies
New Guidelines
http://www.chestnet.org/accp/guidelines/accp-antithrombotic-guidelines-9th-ed-now-available
ACCP Disclaimer
The ACCP recommends that performance measures for quality
improvement, performance-based reimbursement, and public
reporting purposes should be based on rigorously developed
guideline recommendations. However, not all recommendations
graded highly according to the ACCP grading system (1A, 1B)
are necessarily appropriate for development into such
performance measures, and each one should be analyzed
individually for importance, feasibility, usability, and scientific
acceptability (National Quality Forum criteria). Performance
measures developers should exercise caution in basing
measures on recommendations that are graded 1C, 2A, 2B, and
2C, according to the ACCP Grading System1 as these should
generally not be used in performance measures for quality
improvement, performance-based reimbursement, and public
reporting purposes.
ACCP 9th Edition
General Overview
59
Strategies to Improve VTE Prophylaxis
60
Electronic Alerts to Prevent VTE among
Hospitalized Patients
• Hospital computer system identified patient VTE risk factors
• RCT: no physician alert vs physician alert
Control Alert
group group P
No. 1,251 1,255
Any prophylaxis 15 % 34 % <0.001
VTE at 90 days 8.2 % * 4.9 % 0.001
Major bleeding 1.5 % 1.5 % NS
• Institutional support
• A multidisciplinary team or steering committee
• Reliable data collection and performance tracking
• Specific goals or aims
• A proven QI framework
• Protocols
Moderate All other patients (not in low-risk or high- UFH 5000 units SC q 8
risk category); most medical/surgical hours; OR LMWH q day; OR
patients; respiratory insufficiency, heart UFH 5000 units SC q 12
failure, acute infectious, or inflammatory hours (if weight < 50 kg or
disease age > 75 years); AND
suggest adding IPC
Maynard GA, et al. J Hosp Med 2009 Sep 14. [Epub ahead of print]
Maynard GA, et al. J Hosp Med 2009 Sep 14. [Epub ahead of print]
Conclusions
• VTE remains a substantial health problem in
the US